arrow
D

David Shprecher

Banner Health
H指数:32
被引数:4,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease

帕金森病患者住院期间吞咽困难管理的专家共识建议

2026-01-050
OA
Conjugal Synucleinopathies: A Clinicopathologic Study
2024-04-100
PRE
Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium
2024-02-135
PRE
Comorbid neurotrauma increases neurodegenerativerelevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium
SLEEP
IF4.9
2024-01-054
OA
Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort

在社区尸检队列中,路易体痴呆,帕金森病痴呆和阿尔茨海默氏痴呆的纵向运动下降

2023-07-082
PRE
Continued Validation of the RBD Symptom Severity Scale (RBDSSS) in Participants of the North American Prodromal Synucleinopathy (NAPS) Consortium
2023-04-250
PRE
Baseline characteristics of the North American prodromal Synucleinopathy cohort
2023-02-0826
OA
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease: A Randomized Controlled Trial
2022-12-0127
PRE
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021)

抗tau单克隆抗体gosuranemab治疗进行性核上性麻痹的安全性和有效性: 一项2期,随机,安慰剂对照试验 (8月,10.1038/s41591-021-01455-x,2021)

2022-10-171
OA
SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
2022-07-1127
OAAI
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
2021-09-1498
OA